Accepted Article This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ejp.1209 This article is protected by copyright. All rights reserved Article Type: Original Article Clinical testing of three novel transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonists in a pharmacodynamic intradermal capsaicin model E. Sjögren 1 , T. Kullenberg 2 , B. Jonzon 3 , M. Segerdahl 4 , O. Stålberg 5 , M. M. Halldin 6 , A. K. Sundgren-Andersson 7 1) Department of Pharmacy, Uppsala University, BOX 580, SE-751 23 Uppsala, Sweden 2) Swedish Orphan Biovitrum, Solna, Sweden 3) Medical Products Agency, Uppsala, Sweden 4) Lundbeck A/S, Valby, Denmark 5) Department of Medicinal Chemistry, Division of Analytical Pharmaceutical Chemistry, Uppsala University, Sweden 6) AlzeCure Foundation, Karolinska Institute Science Park, SE-141 57 Huddinge, Sweden 7) AstraZeneca GMD, 200 Orchard Ridge Dr, Gaithersburg, MD20878, USA Original article Running head: Testing analgesic potential early in drug development Correspondence to: A. K. Sundgren-Andersson AstraZeneca GMD, 200 Orchard Ridge Dr, Gaithersburg, MD20878, USA Phone: +1 202 450 0834 E-mail: anna.sundgren-andersson@astrazeneca.com Funding source: Funded by AstraZeneca AB in Sweden. This research did not receive any other specific grant from funding agencies in the public, commercial, or not-for-profit sectors.